The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

If you have certain forms of breast cancer, your doctor might suggest Kadcyla (ado-trastuzumab emtansine) as a treatment option. It’s a prescription drug used to treat HER2-positive (HER2+) breast ...

Roche’s Kadcyla needs some oomph, and the Swiss drugmaker’s new data might just do the trick. The company is teeing up a new filing for its next-generation breast cancer drug, hoping to gin up more ...

Kadcyla outperformed Herceptin regarding overall- and invasive disease-free survival in patients with HER2-positive early breast cancer that still had remaining invasive disease after undergoing ...

Roche’s breast cancer drug Kadcyla is set for regular NHS funding in England after the company finally agreed a deal with NICE. The row over Kadcyla has lasted three years, and has been one of the ...

All of the women in the study had progressed on two or more HER2-targeted therapies, including Herceptin (trastuzumab) and Tykerb (lapatinib). Kadcyla (ado-trastuzumab emtansine; T-DM1) reduced the ...

The approval is based on data showing Kadcyla cut the risk of disease recurring by half compared to Herceptin in the adjuvant setting for specific patients with HER2-positive early breast cancer The ...

As biosimilar competition to Herceptin ramps up, Roche is looking to bolster its position in HER2-positive breast cancer with a new indication for Kadcyla. The Swiss pharma firm has announced that it ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive long-term follow-up data from the pivotal, Phase III ...

How do you put a price on life? How would you know where to start? In the case of the independent NHS watchdog, the National Institute for Health and Care Excellence (Nice), there is a points system, ...

– Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date – SOUTH SAN FRANCISCO, Calif. — Genentech, a member of the ...